Replacement techniques to reduce animal experiments in drug and nanoparticle development
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ik Sup Jin | - |
dc.contributor.author | Moon Sup Yoon | - |
dc.contributor.author | Chun‑Woong Park | - |
dc.contributor.author | Jin Tae Hong | - |
dc.contributor.author | Youn Bok Chung | - |
dc.contributor.author | Jin‑Seok Kim | - |
dc.contributor.author | Dae Hwan Shin | - |
dc.date.available | 2021-02-22T05:35:27Z | - |
dc.date.issued | 2020-04 | - |
dc.identifier.issn | 2093-5552 | - |
dc.identifier.issn | 2093-6214 | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/2467 | - |
dc.description.abstract | Background Animals have been used for the testing of new drugs and nanoparticles to determine their safety and effectiveness before application in humans. Numerous drugs and nanoparticles have been developed through animal tests, and development in medical nanotechnology is progressing rapidly. However, a good experiment requires many animals. The primary measures to reduce animal experiments include reducing the number of animals used in each experiment and replacing laboratory animals with inanimate, cellular, or inferior animals to reduce sacrifices. Area covered Developing nanoparticles using simulations rather than experiments may be another alternative. Instead of animals, human cells or animal-derived organs, tissues, or cells could be used in experiments. These methods allow rapid toxicity and efficacy testing at low cost. However, the disadvantage of these methods is that they cannot accurately replicate the complex interrelationships between human organs, biological reactions to specific routes of administration, or toxicity of substances resulting from metabolic processes. To overcome these shortcomings of in vitro tests, new technologies such as organoids and organ-on-chips are progressing. These can be used to quickly examine the efficacy of newly developed drugs and nanoparticles and can be useful in developing patient-tailored agents. Expert opinion These technologies offer some promise but it is still difficult to entirely replace animal experiments. However, the scope of methods to replace experimental animals is widening, suggesting the potential to refine, reduce, and ultimately replace animal testing. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 한국약제학회 | - |
dc.title | Replacement techniques to reduce animal experiments in drug and nanoparticle development | - |
dc.title.alternative | Replacement techniques to reduce animal experiments in drug and nanoparticle development | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.1007/s40005-020-00487-8 | - |
dc.identifier.scopusid | 2-s2.0-85084038922 | - |
dc.identifier.bibliographicCitation | Journal of Pharmaceutical Investigation, v.50, no.3, pp 327 - 335 | - |
dc.citation.title | Journal of Pharmaceutical Investigation | - |
dc.citation.volume | 50 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 327 | - |
dc.citation.endPage | 335 | - |
dc.identifier.kciid | ART002587441 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Animal experiment replacement | - |
dc.subject.keywordAuthor | Biochip | - |
dc.subject.keywordAuthor | Organoid | - |
dc.subject.keywordAuthor | Drug development | - |
dc.subject.keywordAuthor | Animal ethics | - |
dc.subject.keywordAuthor | Nanoparticle | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs40005-020-00487-8 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.